Hours before the Christmas weekend, GRANGEX announced a Royalty and off-take agreement with Anglo Am...
Redeye briefly comments on the announcement of an indication expansion made by Initiator Pharma earl...
Redeye comments on NeoDynamics’ rights issue of approximately SEK25m.
Redeye comments on Nito Games' preliminary figures for Q4, which exceed our expectations by 20% on t...
Q4e: 3.5% y-o-y revenue decline, 16.7% EBITDA margin Updating estimates after close of SDR acquisiti...
Redeye in this note briefly comments on the latest happenings in the 879 patent litigation process.
Q4 report due on Tuesday 6 February No major estimate changes, bid still in focus 12x '24e EV/EBIT, ...
Redeye adjusts its estimates following ADDvise’s recent announcement of the acquisitions of Axeleris...
IRLAB Therapeutics has announced a new loan facility of up to SEK55m with Formue Nord to support its...
Redeye is intrigued by today’s news that Saniona has selected an additional clinical candidate, the ...
Sprint Bioscience is looking to replace Decipher as a partner for VPS34 as soon as the project is ha...
Q-linea finishes 2023 on a positive note as the company has placed the first two US ASTar systems.
Redeye is encouraged to see RemaSawco winning another major order amounting to SEK21m.
Last week, Netmore press released that it has signed a non-binding letter of intent (LOI) to acquire...
Redeye is positive towards today’s news that Saniona has selected SAN2355 as the first clinical cand...
Redeye comments on the news that IRLAB has entered into a loan agreement with Formue Nord.
This morning Strax announced it will sell Urbanista to its debt holders P Capital Partners AB (PCP) ...
Redeye revises its fair value range upwards after correcting a previous error about the treatment of...
Watch the replay of Egetis Therapeutics' capital markets day.
We cut '24e-'25e adj. EBIT by 63-36%EBIT recovery delayed into 2024'24e-'25e EV/EBIT 30x-10xTough bu...
